<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Chem.</journal-id>
<journal-title>Frontiers in Chemistry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Chem.</abbrev-journal-title>
<issn pub-type="epub">2296-2646</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">918116</article-id>
<article-id pub-id-type="doi">10.3389/fchem.2022.918116</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Chemistry</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Synthesis of Melatonin Derivatives and the Neuroprotective Effects on Parkinson&#x2019;s Disease Models of <italic>Caenorhabditis elegans</italic>
</article-title>
<alt-title alt-title-type="left-running-head">He et al.</alt-title>
<alt-title alt-title-type="right-running-head">Melatonin Derivatives and the Neuroprotective Effects</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Li</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1725860/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Du</surname>
<given-names>Jing-Jing</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Jun-Jie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Meng-Ting</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Luo</surname>
<given-names>Lu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Bao-Qiong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Xiang-Zhi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Wen-Zhe</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1777290/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ma</surname>
<given-names>Ai-Jun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1682473/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Feng</surname>
<given-names>Na</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1786556/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>School of Biotechnology and Health Sciences</institution>, <institution>Wuyi University</institution>, <addr-line>Jiangmen</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>State Key Laboratory of Quality Research in Chinese Medicine</institution>, <institution>Macau University of Science and Technology</institution>, <addr-line>Macau</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1586722/overview">Xi Zheng</ext-link>, The State University of New Jersey, United States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/573915/overview">Peng Fu</ext-link>, Ocean University of China, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1782542/overview">Feng Cai</ext-link>, Shandong University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Ai-Jun Ma, <email>wyuchemmaj@126.com</email>; Na Feng, <email>wyuchemfn@126.com</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Organic Chemistry, a section of the journal Frontiers in Chemistry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>10</volume>
<elocation-id>918116</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>04</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>04</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 He, Du, Zhou, Chen, Luo, Li, Zhang, Ma, Ma and Feng.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>He, Du, Zhou, Chen, Luo, Li, Zhang, Ma, Ma and Feng</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Melatonin (MT) is a hormone with antioxidant activity secreted by the pineal gland in the human brain, which is highly efficient in scavenging free radicals and plays an important role in the neuro-immuno-endocrine system. Emerging evidence showed that MT supplementation was a potential therapeutic strategy for Parkinson&#x2019;s disease (PD), which inhibits pathways associated with oxidative stress in PD. In this study, we reported a C7-selective olefination of melatonin under rhodium catalysis with the aid of P<sup>III</sup>-directing groups and synthesized 10 new melatonin-C7-cinnamic acid derivatives (6a&#x2013;6j). The antioxidant potential of the compounds was evaluated both by ABTS and ORAC methods. Among these newly synthesized melatonin derivatives, 6a showed significantly higher activity than MT at 10<sup>&#x2212;5</sup>&#xa0;M. In the transgenic <italic>Caenorhabditis elegans</italic> model of PD, 6a significantly reduces alpha-synuclein aggregation and dopaminergic neuronal damage in nematodes while reducing intracellular ROS levels and recovers behavioral dysfunction induced by dopaminergic neurodegeneration. Further study of the mechanism of action of this compound can provide new therapeutic ideas and treatment strategies for PD.</p>
</abstract>
<kwd-group>
<kwd>derivative of melatonin</kwd>
<kwd>synthesis</kwd>
<kwd>antioxidant activity</kwd>
<kwd>
<italic>C. elegans</italic>
</kwd>
<kwd>Parkinson&#x2019;s disease</kwd>
</kwd-group>
<contract-num rid="cn001">2020FKZX01 2019WGALH12 2019td02</contract-num>
<contract-num rid="cn002">2019KTSCX184 2020KCXTD036 2021KQNCX101</contract-num>
<contract-sponsor id="cn001">Wuyi University<named-content content-type="fundref-id">10.13039/501100007310</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Department of Education of Guangdong Province<named-content content-type="fundref-id">10.13039/501100010226</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Melatonin (MT), secreted by the midbrain pineal gland and some peripheral tissues, is a tryptophan metabolite that activates multiple intracellular signaling pathways (<xref ref-type="bibr" rid="B29">Pohanka et al., 2011</xref>) and has a variety of physiological effects, such as regulating circadian rhythms, scavenging free radicals, enhancing immunity, and inhibiting oxidation of biomolecules (<xref ref-type="bibr" rid="B43">Yu et al., 2000</xref>; <xref ref-type="bibr" rid="B35">Skene and Swaab., 2003</xref>; <xref ref-type="bibr" rid="B41">Wu et al., 2004</xref>). In addition, melatonin has protective effects against neurodegenerative diseases (<xref ref-type="bibr" rid="B31">Rudnitskaya et al., 2015</xref>).</p>
<p>Parkinson&#x2019;s disease (PD) is a neurodegenerative disease with motor and non-motor symptoms characterized by the loss of dopaminergic neurons in the nigrostriatal and the formation of Lewy body proteins (<xref ref-type="bibr" rid="B8">Calabrese et al., 2018</xref>; <xref ref-type="bibr" rid="B6">Bouca-Machado et al., 2019</xref>). The main features of PD are resting tremor, rigidity, and motor retardation (<xref ref-type="bibr" rid="B23">Mann and Yates, 1982</xref>; <xref ref-type="bibr" rid="B36">Smeyne and Jackson-Lewis, 2005</xref>; <xref ref-type="bibr" rid="B17">Jankovic and Stacy., 2007</xref>; <xref ref-type="bibr" rid="B14">Hirsch et al., 2012</xref>). This may be due to the selective loss of dopaminergic (DA) neurons in the substantia nigra densa (SN), resulting in neurological dysfunction (<xref ref-type="bibr" rid="B11">Delenclos et al., 2016</xref>). Pathologically, PD is also characterized by the formation of alpha-synuclein (&#x3b1;-syn) aggregates. The pathological process of PD involves multiple pathways, including apoptosis, autophagy, oxidative stress, <italic>&#x3b1;</italic>-syn aggregation, and alterations in neurotransmitters (<xref ref-type="bibr" rid="B27">Olzmann et al., 2010</xref>; <xref ref-type="bibr" rid="B24">Martinez et al., 2017</xref>; <xref ref-type="bibr" rid="B39">Aditi and Verma, 2019</xref>; <xref ref-type="bibr" rid="B7">Brunetti et al., 2020</xref>).</p>
<p>There is emerging evidence supporting the impact of oxidative stress on PD, and therefore, drugs with antioxidant activity are expected to be a potential treatment for PD (<xref ref-type="bibr" rid="B25">Moosmann and Behl, 2002</xref>; <xref ref-type="bibr" rid="B1">Abou-Sleiman et al., 2006</xref>; <xref ref-type="bibr" rid="B40">Weber and Ernst, 2006</xref>; <xref ref-type="bibr" rid="B33">Sayre et al., 2008</xref>). Studies suggest that MT supplementation is a therapeutic approach for PD disorder. The use of MT inhibits a number of pathways associated with oxidative stress response, <italic>&#x3b1;</italic>-syn aggregation, and dopamine loss in PD (<xref ref-type="bibr" rid="B10">Chen et al., 2002</xref>; <xref ref-type="bibr" rid="B44">Zarranz et al., 2004</xref>; <xref ref-type="bibr" rid="B4">Berendse et al., 2010</xref>). MT may also improve some non-motor symptoms in PD patients.</p>
<p>The nematode <italic>Caenorhabditis elegans</italic> (<italic>C. elegans</italic>) is a powerful genetic model system for exploring PD and related molecular mechanisms (<xref ref-type="bibr" rid="B26">Nass and Chen, 2008</xref>; <xref ref-type="bibr" rid="B2">Anand et al., 2020</xref>). In this study, we used two well-established <italic>C. elegans</italic> models to assess the anti-Parkinsonian effects of melatonin derivatives and to explore their associated potential neuroprotective mechanisms.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Materials and Strains</title>
<p>
<sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were both performed on a 500&#xa0;MHz Bruker NMR spectrometer using TMS as an internal standard (chloroform-<italic>d</italic> as the solvent). Mass spectra were carried out using a Thermo Fisher LCQ Fleet LC-MS mass spectrometer. All reagents used were of analytical grade.</p>
<p>Strains: Bristol N2: wild-type N2 nematode; NL5901: pkIs2386 [unc-54p:&#x3b1;-synuclein:YFP &#x2b; unc-119 (&#x2b;)], a transgenic nematode model of PD disorder expressing yellow fluorescent protein-tagged human <italic>&#x3b1;</italic>-synuclein in muscle; BZ555: egIs1 [dat-1p:GFP], pharmacological model of PD disorder nematode, dat-1 encodes a plasma membrane dopamine transporter protein labelled with a green fluorescent mono-white that can be observed as bright green fluorescence at the junctions between dopamine neuronal soma cells, purchased from the CGC (<italic>Caenorhabditis</italic> Genetics Center); <italic>E. coli</italic> OP50: <italic>Escherichia coli</italic> OP50, uracil leakage mutant strain, used as normal food for feeding <italic>C. elegans</italic>.</p>
</sec>
<sec id="s2-2">
<title>Synthesis of 6a&#x2013;6j</title>
<p>Our group designed a P<sup>III</sup>-directing group (<italic>N</italic>-P<italic>t</italic>Bu<sub>2</sub>), which directed C7-H functionalization of melatonin with olefins through rhodium catalysis. (<xref ref-type="bibr" rid="B5">Borah and Shi, 2018</xref>). We describe the development of the decarbonylative cross-couplings (<xref ref-type="bibr" rid="B46">Zhao and Yu, 2008</xref>; <xref ref-type="bibr" rid="B20">Lei et al., 2015</xref>) of carboxylic acids with melatonin at the C7 position by P<sup>III</sup>-chelation-assisted Rh<sup>I</sup>-catalyzed C-C bond activation (<xref ref-type="bibr" rid="B30">Qiu et al., 2019</xref>).</p>
<p>The decarbonylative reaction was further optimized with substituted cinnamic acid 4 as a partner to produce the melatonin C7-olefination products. We found that the reaction achieved optimal efficiency and selectivity with 2.5 equiv. of Boc<sub>2</sub>O in the presence of 5.0&#xa0;mol% Rh(cod)<sub>2</sub>OTf as a catalyst. Product 5 was obtained after reaction at 120&#xb0;C for 18&#xa0;h under a nitrogen atmosphere. Furthermore, the directing group (P<italic>t</italic>Bu<sub>2</sub>) could be easily removed by TBAF in THF, and N-free melatonin derivatives 6 were isolated at the yields of 47&#x2013;67% (<xref ref-type="bibr" rid="B13">Han et al., 2019</xref>; <xref ref-type="bibr" rid="B30">Qiu et al., 2019</xref>) <xref ref-type="fig" rid="F8">Scheme 1</xref>.</p>
<fig id="F8" position="float">
<label>SCHEME 1</label>
<caption>
<p>Synthesis route for compounds 6a&#x223c; 6j.</p>
</caption>
<graphic xlink:href="fchem-10-918116-g008.tif"/>
</fig>
</sec>
<sec id="s2-3">
<title>N-(2-(5-Methoxy-7-Styryl-1h-Indol-3-yl)ethyl)acetamide (6a)</title>
<p>Light yellow oil. 67% yield. <sup>1</sup>H NMR (500&#xa0;MHz, Chloroform-<italic>d</italic>) <italic>&#x3b4;</italic>: 8.47 (s, 1H), 7.60&#x223c;7.49 (m, 2H), 7.44&#x223c;7.35 (m, 2H), 7.35&#x223c;7.27 (m, 2H), 7.18 (s, 1H), 7.09 (t, <italic>J</italic> &#x3d; 2.0 Hz, 2H), 7.03 (d, <italic>J</italic> &#x3d; 2.3 Hz, 1H), 5.62 (s, 1H), 3.92 (s, 3H), 3.62 (q, <italic>J</italic> &#x3d; 6.5 Hz, 2H), 2.97 (t, <italic>J</italic> &#x3d; 6.8 Hz, 2H), and 1.94 (s, 3H); <sup>13</sup>C NMR (125&#xa0;MHz, chloroform-<italic>d</italic>) <italic>&#x3b4;</italic>: 170.2, 154.4, 137.2, 130.5, 129.8, 128.8, 128.5, 127.9, 126.5, 124.3, 122.9, 122.3, 113.2, 109.9, 100.7, 56.1, 39.8, 25.3, and 23.4; LC-MS (ESI) <italic>m/z</italic>: calcd. for C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub> {[M &#x2b; Na]<sup>&#x2b;</sup>} 357.1573, found 357.1572.</p>
<p>The details of compounds 6b&#x2013;6j can be found in the <xref ref-type="sec" rid="s10">Supplementary Material S1</xref>.</p>
</sec>
<sec id="s2-4">
<title>ABTS Method</title>
<p>The ABTS assay was performed in accordance with a previously reported procedure (<xref ref-type="bibr" rid="B34">Schaich et al., 2015</xref>; <xref ref-type="bibr" rid="B37">Sommer et al., 2022</xref>). A volume of 5&#xa0;ml of 7&#xa0;mmol/L ABTS and 88&#xa0;&#x3bc;L of 140&#xa0;mmol/L potassium persulfate were mixed and left for 12&#xa0;h at room temperature in the dark to form an ABTS<sup>&#x2b;</sup> free radical reserve solution. The reserve liquid was relatively stable at room temperature away from the light. Before use, it was diluted into the working liquid with ultra-pure water, and its absorbance was required to be 0.7 &#xb1; 0.02&#xa0;at 30&#xb0;C and a wavelength of 734&#xa0;nm. The samples were prepared with DMSO into 5, 10, 20, and 40&#xa0;&#x3bc;g/ml sample solutions for later use. During the determination, 100&#xa0;&#x3bc;L of ABTS working solution was added to each well of the 96-well microtitration plate, and then 100&#xa0;&#x3bc;L of sample solution at different concentrations was added to shake and mix. After 10 min, the absorbance at 734&#xa0;nm was determined, and 100&#xa0;&#x3bc;L of ABTS working solution mixed with 100&#xa0;&#x3bc;L of DMSO was used to determine the blank absorbance A<sub>0</sub>. The absorbance of a 100&#xa0;&#x3bc;L sample mixed with 100&#xa0;&#x3bc;L of DMSO was defined as Ar. For each determination, experiments were performed in triplicate.</p>
<p>The radical scavenging rate of ABTS is calculated using the following formula: ABTS free radical scavenging rate (%) &#x3d; [1 &#x2212; (At &#x2212; Ar)/A<sub>0</sub>] &#xd7; 100%.</p>
</sec>
<sec id="s2-5">
<title>ORAC Method</title>
<p>The ORAC method was performed as described previously (<xref ref-type="bibr" rid="B15">Huang et al., 2002</xref>; <xref ref-type="bibr" rid="B28">Ou et al., 2002</xref>) with slight modification. The reaction was carried out in 75&#xa0;mM phosphate buffer (pH 7.4), while the addition of antioxidant substances produced more stable fluorescent signal that could reflect the antioxidant capacity.</p>
<p>A volume of 50&#xa0;&#xb5;L of samples to be tested or different concentrations of Trolox working solution (0.10, 0.08, 0.06, 0.04, and 0.02&#xa0;mmol/L) were added to a 96-well plate, followed by the addition of 100&#xa0;&#xb5;L of FL working solution (8.4 &#xd7; 10<sup>&#x2013;8</sup>&#xa0;mol/L) and shaking for 30&#xa0;s. The fluorescence value F0 was recorded immediately, and then the reaction was shaken for 3&#xa0;min and incubated at 37&#xa0;&#xb0;C for 10&#xa0;min. A volume of 50&#xa0;&#xb5;L of AAPH working fluid was added to induce the reaction. The excitation wavelength and emission wavelength were 485 and 535&#xa0;nm, respectively, and the fluorescence value Fn was recorded every 2.5&#xa0;min. The reaction was considered to be over when the fluorescence decrease slowed. The initial fluorescence value (F0) is the pore fluorescence intensity reading without AAPH. fn &#x3d; fluorescence value (Fn)/initial fluorescence value (F0); AUC &#x3d; 2 &#xd7; (f0 &#x2b; f1 &#x2b;...&#x2b; fn) &#x2212; f0 &#x2212; fn; NetAUC (ORAC value) &#x3d; AUC<sub>sample</sub> &#x2212; AUC<sub>AAPH</sub>
<sup>&#x2b;</sup>. NetAUC was used to determine the capacity for absorbing free radicals. Here, AUC is the area under the fluorescence decay curve, and NetAUC is the protected area. In addition to the tested sample group, a blank group and an AAPH &#x2b; group (for which 50&#xa0;&#xb5;L of 75&#xa0;mM phosphate-buffered saline (PBS) solution was used as the sample substitution) were also tested. To create a standard curve, different concentrations of Trolox solution were used for the abscissa and NetAUC was used for the ordinate, and the absorption capacity of the sample was expressed as &#x3bc;mol&#xa0;TE/g DW. For each determination, experiments were performed in triplicate.</p>
</sec>
<sec id="s2-6">
<title>Measurement of Reactive Oxygen Species (ROS)</title>
<p>2&#x2032;,7&#x2032;-Dichlorofluorescein diacetate (H<sub>2</sub>DCFDA), a universal oxidative stress indicator, was used as a probe for the detection of intracellular ROS. H<sub>2</sub>DCFDA was oxidized by ROS to form the fluorescent dye dichlorofluorescein (DCF) (<xref ref-type="bibr" rid="B18">Jia et al., 2021</xref>). The fluorescence intensity was proportional to the ROS level in <italic>C. elegans</italic>.</p>
<p>Briefly, age-matched L3 larvae were treated with 10&#xa0;&#x3bc;M&#xa0;MT or <bold>6a</bold> for 24&#xa0;h. Subsequently, 2000 nematodes per group were collected and washed three times with M9 buffer. The nematodes were suspended in 400&#xa0;&#xb5;L of PBS with 1% Tween-20 and homogenized to obtain worm lysate. The protein concentration of the lysate was determined using the BCA protein assay kit. A volume of 50&#xa0;&#x3bc;L of nematode lysate was transferred into a 96-well black microplate and incubated with 50&#xa0;&#x3bc;L of 50&#xa0;&#x3bc;M H<sub>2</sub>DCFDA. Fluorescence intensity (485&#xa0;nm excitation and 590&#xa0;nm emission) was monitored using an enzyme plate reader (<xref ref-type="bibr" rid="B42">Wu et at., 2006</xref>; <xref ref-type="bibr" rid="B21">Liu et al., 2015</xref>; <xref ref-type="bibr" rid="B45">Zhao et al., 2018</xref>).</p>
</sec>
<sec id="s2-7">
<title>&#x3b1;-Synuclein Accumulation Assay</title>
<p>PD pathology usually showed an accumulation of the <italic>&#x3b1;</italic>-syn. We used strain NL5901 to test the effect of MT and 6a on <italic>&#x3b1;</italic>-syn aggregation. The synchronized nematodes were immersed in M9 buffer containing 10&#xa0;&#xb5;M melatonin and 6a for 48&#xa0;h at 20&#xb0;C. L1 worms were transferred to OP50/NGM plates at 20&#xb0;C for 65&#xa0;h (L3 stage), and then the nematodes were transferred to plates containing OP50/NGM/5-fluorodeoxyuridine (FUDR, 0.04&#xa0;mg/ml) and incubated at 20&#xb0;C for 3&#xa0;days. The young adults were washed three times with M9 buffer, then anesthetized with 10% sodium azide, and fixed on slides. The worms were observed using an Olympus BX63 fluorescent microscope to monitor the YFP expression (&#x3b1;-syn aggregation). The fluorescence intensity of each nematode was quantified using ImageJ software (<xref ref-type="bibr" rid="B16">Jadiya et al., 2011</xref>; <xref ref-type="bibr" rid="B12">Govindan et al., 2018</xref>; <xref ref-type="bibr" rid="B3">Anjaneyulu et al., 2020</xref>).</p>
</sec>
<sec id="s2-8">
<title>6-OHDA-Induced Damage to Dopaminergic Neurons</title>
<p>Dopaminergic neuron degeneration was induced by 50&#xa0;mM 6-OHDA in <italic>C. elegans</italic> as described previously (<xref ref-type="bibr" rid="B38">Tucci et al., 2011</xref>). Briefly, the synchronized nematodes were immersed in M9 buffer containing MT or 6a for 48&#xa0;h at 20&#xb0;C, and then L1 worms were transferred to OP50/NGM plates at 20&#xb0;C for 65&#xa0;h (L3 stage), after which they were exposed to 50&#xa0;mM 6-OHDA for 1&#xa0;h. After exposure, the worms were washed with M9 buffer and transferred to OP50/NGM plates containing 0.04&#xa0;mg/ml FUDR for 3 days at 20&#xa0;&#xb0;C for various assays (<xref ref-type="bibr" rid="B9">Chalorak et al., 2021</xref>; <xref ref-type="bibr" rid="B22">Ma et al., 2021</xref>).</p>
</sec>
<sec id="s2-9">
<title>Behavior Assay</title>
<p>In general, N<sub>2</sub> nematodes were treated with 50&#xa0;mM 6-OHDA to induce degenerative lesions in dopamine neurons.</p>
<p>For thrashing assay, synchronized L4 stage nematodes were transferred to a 3-cm diameter Petri dish, 1&#xa0;ml of M9 buffer was added, and after the nematodes were stabilized for 30 s, a Leica M205 FA microscope was used to continuously capture the worms for 10 s. The number of thrashing of the nematodes was counted (<xref ref-type="bibr" rid="B19">Lee et al., 2021</xref>).</p>
<p>For travel distance assay, nematodes of the synchronized L4 stage were transferred from food-containing dishes to non-food dishes and washed three times repeatedly in M9 buffer to remove the remaining food. The distance (mm) and speed (&#xb5;m/sec) of the nematode&#x2019;s movement in 20&#xa0;s were calculated using the Leica M205 FA microscope and finally analyzed using GraphPad Prism software (<xref ref-type="bibr" rid="B32">Sawin et al., 2000</xref>).</p>
</sec>
<sec id="s2-10">
<title>Statistical Analysis</title>
<p>All the experiments were performed in triplicate. The significance of differences between control and treated groups was analyzed by one-way analysis of variance (ANOVA), followed by Bonferroni&#x2019;s method. <italic>p</italic>-values &#x3c; 0.05 were accepted as statistically significant. Graphs were constructed using GraphPad Prism version 8.00.</p>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and Discussion</title>
<sec id="s3-1">
<title>Antioxidant Activity of Melatonin Derivatives <italic>In Vitro</italic>
</title>
<p>In the ABTS method, the antioxidant activity of the 10 derivatives of melatonin at the C7 position, 6a&#x2013;6j, increased in a concentration-dependent manner, and the antioxidant activity of 6a&#x2013;6j was higher than that of melatonin at the same concentration, while the ABTS radical scavenging rate of the 10 derivatives, 6a&#x2013;6j, was higher than that of vitamin C (VC) and MT at low concentrations of 5 and 10&#xa0;&#x3bc;g/ml (<xref ref-type="fig" rid="F1">Figure 1</xref>). These results indicated that the derivatization of melatonin at the C7 position could improve its antioxidant activity.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>ABTS method for measuring the antioxidant activity of 6a&#x223c; 6j.</p>
</caption>
<graphic xlink:href="fchem-10-918116-g001.tif"/>
</fig>
<p>In the ORAC method, at the same concentration (4&#xa0;&#x3bc;g/ml), the antioxidant activity of derivatives 6b&#x2013;6j at the C7 position of melatonin was lower than that of melatonin, whereas the antioxidant activity of 6a was higher than that of MT (<xref ref-type="fig" rid="F2">Figure 2</xref>). This suggested that the derivatization of melatonin at the C7 position may increase its antioxidant activity.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>ORAC method for measuring the antioxidant activity of 6a&#x223c; 6j.</p>
</caption>
<graphic xlink:href="fchem-10-918116-g002.tif"/>
</fig>
<p>In this study, the antioxidant activity of melatonin derivatives was assessed by two <italic>in vitro</italic> assays, the ABTS method and the ORAC method. Comparing the results of these two methods, we found that the antioxidant activity of 6a, a derivative of melatonin at position C7, was higher than that of MT and the positive control VC as well.</p>
</sec>
<sec id="s3-2">
<title>6a Decreased the ROS Level in <italic>C. elegans</italic>
</title>
<p>To further confirm the antioxidant effect of 6a, we tested the intracellular ROS level in <italic>C. elegans</italic>. We first examined the effect of 6a on the ROS levels in wild-type N2 nematodes. As shown in <xref ref-type="fig" rid="F3">Figure 3</xref>, compared with the untreated group, after treatment with 6a at different concentrations (2, 10, and 50&#xa0;&#xb5;M), the levels of ROS in the nematodes decreased, and 10&#xa0;&#xb5;M of 6a achieved a significant decrease compared with the level in the untreated group (<italic>p</italic> &#x3c; 0.001). Additionally, the ROS levels clearly declined in the 6a group compared with those in the MT group (<italic>p</italic> &#x3c; 0.05). These results are consistent with the <italic>in vitro</italic> antioxidant assay, further demonstrating the antioxidant capacity of 6a. The excellent antioxidant activity of 6a suggests its potential as a therapeutic agent for PD disorders.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Effect of 6a on the ROS level in wild-type.</p>
</caption>
<graphic xlink:href="fchem-10-918116-g003.tif"/>
</fig>
<p>To test this hypothesis, we first examined the effect of 6a on the ROS level in the transgenic nematode model of PD. As shown in <xref ref-type="fig" rid="F4">Figure 4</xref>, compared with the untreated group, after treatment with different concentrations (2, 10, and 50&#xa0;&#xb5;M) of 6a, the levels of ROS in NL5901 worms reduced, and 10&#xa0;&#xb5;M of 6a achieved a significant decrease compared with the level in the untreated group (<italic>p</italic> &#x3c; 0.001), along with a clear decline compared with that in the MT group (<italic>p</italic> &#x3c; 0.05). These results are consistent with the findings in the ROS levels in N2 worms. The regulation of ROS levels in wild-type and NL590 animals by <bold>6a</bold> confirmed its ability to regulate ROS <italic>in vivo</italic>, suggesting that it could reduce ROS-induced acute oxidative damage.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Effect of 6a on the ROS level of the transgenic nematode NL5901.</p>
</caption>
<graphic xlink:href="fchem-10-918116-g004.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>6a Reduced <italic>&#x3b1;</italic>-Synuclein Aggregation in the Transgenic Nematode NL5901</title>
<p>One of the typical features of PD patients is the formation of Lewy bodies in the brain. The accumulation of Lewy bodies exacerbates the neurodegenerative progression in PD. Aggregated <italic>&#x3b1;</italic>-syn, which is known as a major component of Lewy bodies, can be measured in the transgenic NL5901 strain of <italic>C. elegans</italic>. In this strain, human <italic>&#x3b1;</italic>-syn is expressed in muscle cells with a YFP reporter. The fluorescence intensity at the anterior end of the worms indicates the accumulation of <italic>&#x3b1;</italic>-syn. To further confirm the therapeutic effect of 6a on PD, we examined its effect on <italic>&#x3b1;</italic>-syn aggregation. The results showed that, in the group treated with 10&#xa0;&#xb5;M 6a, the YFP fluorescence intensity in NL5901 was reduced compared with that in the untreated control group (<xref ref-type="fig" rid="F5">Figure 5A</xref>). Quantitative analysis of the fluorescence intensity using ImageJ software showed that, in worms treated with 10&#xa0;&#xb5;M 6a (73.92 &#xb1; 1.80), the fluorescence intensity was lowered by 25.65% (<italic>p</italic> &#x3c; 0.001) compared with that in untreated worms (99.45 &#xb1; 2.03). In addition, the 6a-treated group had lower fluorescence intensity than the MT-treated group (81.04 &#xb1; 2.74, <italic>p</italic> &#x3c; 0.05; <xref ref-type="fig" rid="F5">Figure 5B</xref>). These results indicate that the protective effect of 6a occurs by reducing the aggregation of <italic>&#x3b1;</italic>-syn in the PD model.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>
<italic>&#x3b1;</italic>-syn aggregation in NL5901 was decreased by treatment of MT and 6a. <bold>(A)</bold> Representative images of <italic>&#x3b1;</italic>-syn accumulation in different groups of head muscles. <bold>(B)</bold> Quantification of fluorescence intensity in NL5901 using ImageJ software (&#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001).</p>
</caption>
<graphic xlink:href="fchem-10-918116-g005.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>6a Is Protective Against 6-OHDA-Induced Dopaminergic Neuronal Damage</title>
<p>
<italic>C. elegans</italic> contains exactly eight dopaminergic neurons, including two ADEs, four CEPs, and two PDEs (<xref ref-type="fig" rid="F6">Figure 6A</xref>). In the BZ555 strain, all the eight DA neurons were tagged with GFP. Upon exposure to 50&#xa0;mM 6-OHDA, the BZ555 strain showed selective damage in DA neurons. To examine the efficacy of 6a, the viability of the DA neurons was assessed by measuring the loss of expression of the GFP reporter. We found that CEP, ADE, and PDE neurons showed partial GFP loss after 6-OHDA treatment (<xref ref-type="fig" rid="F6">Figure 6B</xref>). When nematodes were pretreated with MT or 6a for 48&#xa0;h at L1, the GFP expression loss was remarkably restored in CEP and ADE neurons (<xref ref-type="fig" rid="F6">Figure 6B</xref>). We further measured the fluorescence intensity in DA neurons using ImageJ software. In nematodes treated with 50&#xa0;mM 6-OHDA (47.41 &#xb1; 2.53), the mean fluorescence (GFP) intensity decreased by about 56% (<italic>p</italic> &#x3c; 0.001) compared with that of untreated nematodes (84.71 &#xb1; 1.25), whereas dopaminergic neurons of nematodes exposed to 6-OHDA after treatment with 10&#xa0;&#xb5;M 6a recovered to 74.28 &#xb1; 1.87 (<italic>p</italic> &#x3c; 0.001), and the mean fluorescence intensity was higher in the 6a-treated group than in the MT-treated group (72.94 &#xb1; 1.09, <italic>p</italic> &#x3c; 0.05; <xref ref-type="fig" rid="F6">Figure 6C</xref>), suggesting that 6a is protective against 6-OHDA-induced dopaminergic neuronal damage and that this protective effect is stronger than that of MT.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Effect of MT and 6a on restoration of 6-OHDA-induced DA neurodegeneration in the BZ555 strain. <bold>(A)</bold> Neuronal circuits in <italic>C. elegans.</italic> <bold>(B)</bold> GFP expression patterns of CEP and ADE in BZ555. <bold>(C)</bold> Quantification of the fluorescence intensity of all eight DA neurons of BZ555. (&#x23;&#x23;&#x23;<italic>p</italic> &#x3c; 0.001, compared with the control; &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001, compared with the 6-OHDA-treated group).</p>
</caption>
<graphic xlink:href="fchem-10-918116-g006.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>6a Recovers Behavioral Dysfunction Induced by DA Neurodegeneration</title>
<p>We next investigated whether 6a improves the functions of DA neurons. The locomotion of worms slows down when they encounter food, referred to as the basal slowing response, which is mediated by mechanosensory DA neurons. In this study, we found that N2 nematodes showed a 72.2% decrease in speed when on NGM plates with food and a 9.7% decrease in basal deceleration induced by 50&#xa0;mM 6-OHDA (<italic>p</italic> &#x3c; 0.001), in terms of food perception behavior. Meanwhile, there was significant recovery from this decline to 69.9% after treatment with 10&#xa0;&#xb5;M 6a (<italic>p</italic> &#x3c; 0.001), and the 6a-treated group showed a better basal deceleration response than the melatonin-treated group (<italic>p</italic> &#x3c; 0.05) (<xref ref-type="fig" rid="F7">Figure 7C</xref>). Similarly, in wild-type N2 nematodes, supplementation with 6a also restored 6-OHDA-induced deficits in DA neuron-associated motor activity, such as increasing the distance traveled and thrashing behavior (<xref ref-type="fig" rid="F7">Figures 7A, B</xref>). These results suggest that 6a recovers the behavioral dysfunction induced by DA neurodegeneration.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Effect of MT and 6a on DA neuronal function. <bold>(A)</bold> Thrashing behavior of N2. <bold>(B)</bold> Travel distances of N2. <bold>(C)</bold> Velocity of N2 in NGM plates with and without food and basal slowing response. (&#x23;&#x23;&#x23;<italic>p</italic> &#x3c; 0.001, compared with the control; &#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.001, compared with the 6-OHDA-treated group).</p>
</caption>
<graphic xlink:href="fchem-10-918116-g007.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>Conclusion</title>
<p>We successfully synthesized 10 melatonin derivatives 6a&#x2013;6j, and their activities were tested using <italic>in vitro</italic> antioxidant assays, ABTS and ORAC. The results showed that the antioxidant activity of melatonin derivative 6a was higher than that of MT. Subsequently, we evaluated the effect of 6a on ROS levels in <italic>C. elegans</italic>. The results showed that 10&#xa0;&#xb5;M 6a significantly reduced the ROS levels in wild-type N2. We also used two PD models of <italic>C. elegans</italic> to investigate the therapeutic effect of 6a on PD<italic>.</italic> We found that 10&#xa0;&#xb5;M 6a significantly reduced the ROS levels and <italic>&#x3b1;</italic>-syn aggregation in NL5901. Treatment of BZ555 with 50&#xa0;mM 6-OHDA reduced the fluorescence intensity of their dopaminergic neuronal cells, which was increased by supplementation with 10&#xa0;&#xb5;M 6a. Finally, we evaluated the capacity of 6a to improve behavioral deficits caused by DA neurodegeneration. The results showed that 10&#xa0;&#xb5;M 6a improved the nematode&#x2019;s behavior in perceiving food and increased its basal rate compared with the findings in the control.</p>
<p>Our conclusions prove that melatonin derivative 6a significantly reduces <italic>&#x3b1;</italic>-syn aggregation and dopaminergic neuronal damage in PD by reducing oxidative stress-induced ROS levels and improves the behavioral impairment caused by DA neurodegeneration. Further study of the mechanism of action of this compound could provide new therapeutic ideas and treatment strategies for PD.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s10">Supplementary Material</xref>; further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>NF, A-JM, and W-ZM designed the work and wrote the manuscript. LH, J-JD, J-JZ, M-TC, and LL carried out the experiments. All authors reviewed the manuscript and agreed to its publication.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This work was supported by the COVID-19 Epidemic Prevention and Control Project of Wuyi University (2020FKZX01), the Department of Education of Guangdong Province (2019KTSCX184, 2020KCXTD036, and 2021KQNCX101), the Hong Kong&#x2013;Macao Joint Research and Development Fund of Wuyi University (2019WGALH12), the Science Foundation for Young Teachers (2019td02) of Wuyi University, the Jiangmen City Science and Technology Basic Research Project (2021030102630004945), and the Innovations in Graduate Education Program (YJS-SFJD-21-01).</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ack>
<p>We thank Liwen Bianji (Edanz) (<ext-link ext-link-type="uri" xlink:href="http://www.liwenbianji.cn">www.liwenbianji.cn</ext-link>) for editing the language of the draft of this article.</p>
</ack>
<sec id="s10">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fchem.2022.918116/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fchem.2022.918116/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.PDF" id="SM1" mimetype="application/PDF" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abou-Sleiman</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Muqit</surname>
<given-names>M. M. K.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>N. W.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Expanding Insights of Mitochondrial Dysfunction in Parkinson&#x27;s Disease</article-title>. <source>Nat. Rev. Neurosci.</source> <volume>7</volume>, <fpage>207</fpage>&#x2013;<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1038/nrn1868</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anand</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Holcom</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Broussalian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chinta</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Lithgow</surname>
<given-names>G. J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Dysregulated Iron Metabolism in <italic>C. elegans</italic> catp-6/ATP13A2 Mutant Impairs Mitochondrial Function</article-title>. <source>Neurobiol. Dis.</source> <volume>139</volume>, <fpage>104786</fpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2020.104786</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anjaneyulu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>R</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Godbole</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Differential Effect of Ayurvedic Nootropics on <italic>C. elegans</italic> Models of Parkinson&#x27;s Disease</article-title>. <source>J. Ayurveda Integr. Med.</source> <volume>11</volume>, <fpage>440</fpage>&#x2013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaim.2020.07.006</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berendse</surname>
<given-names>H. W.</given-names>
</name>
<name>
<surname>Booij</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Francot</surname>
<given-names>C. M. J. E.</given-names>
</name>
<name>
<surname>Bergmans</surname>
<given-names>P. L. M.</given-names>
</name>
<name>
<surname>Hijman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Stoof</surname>
<given-names>J. C.</given-names>
</name>
<etal/>
</person-group> (<year>2001</year>). <article-title>Subclinical Dopaminergic Dysfunction in Asymptomatic Parkinson&#x27;s Disease Patients&#x27; Relatives with a Decreased Sense of Smell</article-title>. <source>Ann. Neurol.</source> <volume>50</volume>, <fpage>34</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1002/ana.1049</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borah</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Rhodium-Catalyzed, Remote Terminal Hydroarylation of Activated Olefins through a Long-Range Deconjugative Isomerization</article-title>. <source>J. Am. Chem. Soc.</source> <volume>140</volume>, <fpage>6062</fpage>&#x2013;<lpage>6066</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.8b03560</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bou&#xe7;a&#x2010;Machado</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Patriarca</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Castro Caldas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alarc&#xe3;o</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>R. M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Measurement Instruments to Assess Functional Mobility in Parkinson&#x27;s Disease: A Systematic Review</article-title>. <source>Mov. Disord. Clin. Pract.</source> <volume>7</volume>, <fpage>129</fpage>&#x2013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1002/mdc3.12874</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brunetti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Di Rosa</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Scuto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stefani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmitz-Linneweber</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Healthspan Maintenance and Prevention of Parkinson&#x27;s-like Phenotypes with Hydroxytyrosol and Oleuropein Aglycone in <italic>C. elegans</italic>
</article-title>. <source>Ijms</source> <volume>21</volume>, <fpage>2588</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21072588</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calabrese</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Santoro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Monti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Crupi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Di Paola</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Latteri</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Aging and Parkinson&#x27;s Disease: Inflammaging, Neuroinflammation and Biological Remodeling as Key Factors in Pathogenesis</article-title>. <source>Free Radic. Biol. Med.</source> <volume>115</volume>, <fpage>80</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2017.10.379</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chalorak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sanguanphun</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Limboonreung</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Meemon</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Neurorescue Effects of Frondoside A and Ginsenoside Rg3 in <italic>C. elegans</italic> Model of Parkinson&#x27;s Disease</article-title>. <source>Molecules</source> <volume>26</volume>, <fpage>4843</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26164843</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S. T.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>J. I.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>E. I.-C.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Melatonin Attenuates MPP&#x2b; -induced Neurodegeneration and Glutathione Impairment in the Nigrostriatal Dopaminergic Pathway</article-title>. <source>J. Pineal Res.</source> <volume>32</volume>, <fpage>262</fpage>&#x2013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1034/j.1600-079X.2002.01871.x</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delenclos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Mclean</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Uitti</surname>
<given-names>R. J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Biomarkers in Parkinson&#x27;s Disease: Advances and Strategies</article-title>. <source>Park. Relat. Disord.</source> <volume>22</volume>, <fpage>s106</fpage>&#x2013;<lpage>s110</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2015.09.048</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Govindan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Amirthalingam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Duraisamy</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Govindhan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sundararaj</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Palanisamy</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Phytochemicals-induced Hormesis Protects <italic>Caenorhabditis elegans</italic> against &#x3b1;-synuclein Protein Aggregation and Stress through Modulating HSF-1 and SKN-1/Nrf2 Signaling Pathways</article-title>. <source>Biomed. Pharmacother.</source> <volume>102</volume>, <fpage>812</fpage>&#x2013;<lpage>822</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.03.128</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Rhodium-Catalyzed Selective C-H Trideuteromethylation of Indole at C7 Position Using Acetic-D6 Anhydride</article-title>. <source>J. Org. Chem.</source> <volume>84</volume>, <fpage>12764</fpage>&#x2013;<lpage>12772</lpage>. <pub-id pub-id-type="doi">10.1021/acs.joc.9b01114</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsch</surname>
<given-names>E. C.</given-names>
</name>
<name>
<surname>Jenner</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Przedborski</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Pathogenesis of Parkinson&#x27;s Disease</article-title>. <source>Mov. Disord.</source> <volume>28</volume>, <fpage>24</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1002/mds.25032</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hampsch-Woodill</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Flanagan</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Prior</surname>
<given-names>R. L.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>High-throughput Assay of Oxygen Radical Absorbance Capacity (ORAC) Using a Multichannel Liquid Handling System Coupled with a Microplate Fluorescence Reader in 96-well Format</article-title>. <source>J. Agric. Food Chem.</source> <volume>50</volume>, <fpage>4437</fpage>&#x2013;<lpage>4444</lpage>. <pub-id pub-id-type="doi">10.1021/jf0201529</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jadiya</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sammi</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mir</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Nazir</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Anti-Parkinsonian Effects of Bacopa Monnieri: Insights from Transgenic and Pharmacological <italic>Caenorhabditis elegans</italic> Models of Parkinson&#x27;s Disease</article-title>. <source>Biochem. Biophysical Res. Commun.</source> <volume>413</volume>, <fpage>605</fpage>&#x2013;<lpage>610</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2011.09.010</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jankovic</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stacy</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson?s Disease</article-title>. <source>Cns Drugs</source> <volume>21</volume>, <fpage>677</fpage>&#x2013;<lpage>692</lpage>. <pub-id pub-id-type="doi">10.2165/00023210-200721080-00005</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Neuroprotective Effects of Palmatine via the Enhancement of Antioxidant Defense and Small Heat Shock Protein Expression in A&#x3b2;-Transgenic <italic>Caenorhabditis elegans</italic>
</article-title>. <source>Oxidative Med. Cell. Longev.</source> <volume>2021</volume>, <fpage>1</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1155/2021/9966223</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Cha</surname>
<given-names>D. S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Neuroprotective Effect of Damaurone D in a <italic>C. elegans</italic> Model of Parkinson&#x27;s Disease</article-title>. <source>Neurosci. Lett.</source> <volume>747</volume>, <fpage>135623</fpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2021.135623</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lei</surname>
<given-names>Z.-Q.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.-S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Group Exchange between Ketones and Carboxylic Acids through Directing Group Assisted Rh-Catalyzed Reorganization of Carbon Skeletons</article-title>. <source>J. Am. Chem. Soc.</source> <volume>137</volume>, <fpage>5012</fpage>&#x2013;<lpage>5020</lpage>. <pub-id pub-id-type="doi">10.1021/ja512003d</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Banskota</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Critchley</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hafting</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Prithiviraj</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Neuroprotective Effects of the Cultivated Chondrus Crispus in a <italic>C. elegans</italic> Model of Parkinson&#x27;s Disease</article-title>. <source>Mar. Drugs</source> <volume>13</volume>, <fpage>2250</fpage>&#x2013;<lpage>2266</lpage>. <pub-id pub-id-type="doi">10.3390/md13042250</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Protective Effects of Baicalin in a <italic>Caenorhabditis elegans</italic> Model of Parkinson&#x27;s Disease</article-title>. <source>Toxicol. Res.</source> <volume>10</volume>, <fpage>409</fpage>&#x2013;<lpage>417</lpage>. <pub-id pub-id-type="doi">10.1093/toxres/tfaa107</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mann</surname>
<given-names>D. M. A.</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>P. O.</given-names>
</name>
</person-group> (<year>1982</year>). <article-title>Pathogenesis of Parkinson&#x27;s Disease</article-title>. <source>Archives Neurology</source> <volume>39</volume>, <fpage>545</fpage>&#x2013;<lpage>549</lpage>. <pub-id pub-id-type="doi">10.1001/archneur.1982.00510210015004</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>G. A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>C . Elegans as a Model System to Accelerate Discovery for Parkinson Disease</article-title>. <source>Curr. Opin. Genet. Dev.</source> <volume>44</volume>, <fpage>102</fpage>&#x2013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/j.gde.2017.02.011</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moosmann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Behl</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Antioxidants as Treatment for Neurodegenerative Disorders</article-title>. <source>Expert Opin. Investigational Drugs</source> <volume>11</volume>, <fpage>1407</fpage>&#x2013;<lpage>1435</lpage>. <pub-id pub-id-type="doi">10.1517/13543784.11.10.1407</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nass</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>
<italic>Caenorhabditis elegans</italic> Models of Human Neurodegenerative Diseases</article-title>. <source>Humana Press</source> <volume>6615</volume>, <fpage>91</fpage>&#x2013;<lpage>101</lpage>. <comment>978-1-58829-933-8</comment>. <pub-id pub-id-type="doi">10.1007/978-1-59745-285-4_12</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olzmann</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Bordelon</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Muly</surname>
<given-names>E. C.</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>H. D.</given-names>
</name>
<name>
<surname>Levey</surname>
<given-names>A. I.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Selective Enrichment of DJ-1 Protein in Primate Striatal Neuronal Processes: Implications for Parkinson&#x27;s Disease</article-title>. <source>J. Comp. Neurol.</source> <volume>500</volume>, <fpage>585</fpage>&#x2013;<lpage>599</lpage>. <pub-id pub-id-type="doi">10.1002/cne.21191</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hampsch-Woodill</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Flanagan</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Deemer</surname>
<given-names>E. K.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Analysis of Antioxidant Activities of Common Vegetables Employing Oxygen Radical Absorbance Capacity (ORAC) and Ferric Reducing Antioxidant Power (FRAP) Assays: a Comparative Study</article-title>. <source>J. Agric. Food Chem.</source> <volume>50</volume>, <fpage>3122</fpage>&#x2013;<lpage>3128</lpage>. <pub-id pub-id-type="doi">10.1021/jf0116606</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pohanka</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Alzheimer&#x27;s Disease and Related Neurodegenerative Disorders: Implication and Counteracting of Melatonin</article-title>. <source>Jab</source> <volume>9</volume>, <fpage>185</fpage>&#x2013;<lpage>196</lpage>. <pub-id pub-id-type="doi">10.2478/v10136-011-0003-6</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>PIII -Chelation-Assisted Indole C7-Arylation, Olefination, Methylation, and Acylation with Carboxylic Acids/Anhydrides by Rhodium Catalysis</article-title>. <source>Angew. Chem. Int. Ed.</source> <volume>58</volume>, <fpage>1504</fpage>&#x2013;<lpage>1508</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201813182</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rudnitskaya</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Maksimova</surname>
<given-names>K. Y.</given-names>
</name>
<name>
<surname>Muraleva</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Logvinov</surname>
<given-names>S. V.</given-names>
</name>
<name>
<surname>Yanshole</surname>
<given-names>L. V.</given-names>
</name>
<name>
<surname>Kolosova</surname>
<given-names>N. G.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Beneficial Effects of Melatonin in a Rat Model of Sporadic Alzheimer&#x27;s Disease</article-title>. <source>Biogerontology</source> <volume>16</volume>, <fpage>303</fpage>&#x2013;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1007/s10522-014-9547-7</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawin</surname>
<given-names>E. R.</given-names>
</name>
<name>
<surname>Ranganathan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Horvitz</surname>
<given-names>H. R.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>
<italic>C. elegans</italic> Locomotory Rate Is Modulated by the Environment through a Dopaminergic Pathway and by Experience through a Serotonergic Pathway</article-title>. <source>Neuron</source> <volume>26</volume>, <fpage>619</fpage>&#x2013;<lpage>631</lpage>. <pub-id pub-id-type="doi">10.1016/S0896-6273(00)81199-X</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sayre</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Oxidative Stress and Neurotoxicity</article-title>. <source>Chem. Res. Toxicol.</source> <volume>21</volume>, <fpage>172</fpage>&#x2013;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1021/tx700210j</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaich</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Hurdles and Pitfalls in Measuring Antioxidant Efficacy: A Critical Evaluation of ABTS, DPPH, and ORAC Assays</article-title>. <source>J. Funct. Foods</source> <volume>14</volume>, <fpage>111</fpage>&#x2013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2015.01.043</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skene</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Swaab</surname>
<given-names>D. F.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Melatonin Rhythmicity: Effect of Age and Alzheimer&#x27;s Disease</article-title>. <source>Exp. Gerontol.</source> <volume>38</volume>, <fpage>199</fpage>&#x2013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1016/S0531-5565(02)00198-5</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smeyne</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Jackson-Lewis</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>The MPTP Model of Parkinson&#x27;s Disease</article-title>. <source>Mol. Brain Res.</source> <volume>134</volume>, <fpage>57</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.molbrainres.2004.09.017</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sommer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kunzmann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Stuthmann</surname>
<given-names>L. E.</given-names>
</name>
<name>
<surname>Springer</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The Antioxidative Potential of Sea Grapes (Caulerpa Lentillifera, Chlorophyta) Can Be Triggered by Light to Reach Comparable Values of Pomegranate and Other Highly Nutritious Fruits</article-title>. <source>Plant Physiol. Rep.</source> <volume>27</volume>, <fpage>186</fpage>&#x2013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1007/s40502-021-00637-6</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tucci</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Harrington</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Caldwell</surname>
<given-names>K. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Modeling Dopamine Neuron Degeneration in <italic>Caenorhabditis elegans</italic>
</article-title>. <source>Humana Press</source> <volume>793</volume>, <fpage>129</fpage>&#x2013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-61779-328-8_9</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verma</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ravindranath</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>CaV1.3 L-type Calcium Channels Increase the Vulnerability of Substantia Nigra Dopaminergic Neurons in MPTP Mouse Model of Parkinson&#x27;s Disease</article-title>. <source>Front. Aging Neurosci.</source> <volume>11</volume>, <fpage>382</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2019.00382</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weber</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Ernst</surname>
<given-names>M. E.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Antioxidants, Supplements, and Parkinson&#x27;s Disease</article-title>. <source>Ann. Pharmacother.</source> <volume>40</volume>, <fpage>935</fpage>&#x2013;<lpage>938</lpage>. <pub-id pub-id-type="doi">10.1345/aph.1G551</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.-H.</given-names>
</name>
<name>
<surname>Feenstra</surname>
<given-names>M. G. P.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.-N.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.-Y.</given-names>
</name>
<name>
<surname>Torano&#x303;</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Van Kan</surname>
<given-names>H. J. M.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>Molecular Changes Underlying Reduced Pineal Melatonin Levels in Alzheimer Disease: Alterations in Preclinical and Clinical Stages</article-title>. <source>J. Clin. Endocrinol. Metabolism</source> <volume>88</volume>, <fpage>5898</fpage>&#x2013;<lpage>5906</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2003-030833</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Butko</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Christen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>W. L.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Amyloid- -Induced Pathological Behaviors Are Suppressed by Ginkgo Biloba Extract EGb 761 and Ginkgolides in Transgenic <italic>Caenorhabditis elegans</italic>
</article-title>. <source>J. Neurosci.</source> <volume>26</volume>, <fpage>13102</fpage>&#x2013;<lpage>13113</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3448-06.2006</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>C.-X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>C.-B.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.-F.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>X.-D.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>G.-C.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Selective MT2 Melatonin Receptor Antagonist Blocks Melatonin-Induced Antinociception in Rats</article-title>. <source>Neurosci. Lett.</source> <volume>282</volume>, <fpage>161</fpage>&#x2013;<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1016/S0304-3940(00)00883-1</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarranz</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Alegre</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>G&#xf3;mez-Esteban</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Lezcano</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ros</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ampuero</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>The New Mutation, E46K, of &#x3b1;-synuclein Causes Parkinson and Lewy Body Dementia</article-title>. <source>Ann. Neurol.</source> <volume>55</volume>, <fpage>164</fpage>&#x2013;<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1002/ana.10795</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Antioxidant Peptides Derived from the Hydrolyzate of Purple Sea Urchin (Strongylocentrotus Nudus) Gonad Alleviate Oxidative Stress in <italic>Caenorhabditis elegans</italic>
</article-title>. <source>J. Funct. Foods</source> <volume>48</volume>, <fpage>594</fpage>&#x2013;<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2018.07.060</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Rhodium-Catalyzed Regioselective C&#x2212;H Functionalization via Decarbonylation of Acid Chlorides and C&#x2212;H Bond Activation under Phosphine-free Conditions</article-title>. <source>J. Am. Chem. Soc.</source> <volume>130</volume>, <fpage>8136</fpage>&#x2013;<lpage>8137</lpage>. <pub-id pub-id-type="doi">10.1021/ja803154h</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>